Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
June 16, 2026

Remibrutinib for treating chronic spontaneous urticaria after inadequate H1 antihistamine response as of June 2026

MARA Rating Company June 16, 2026

Wegovy / semaglutide for weight Management in Adults With Obesity or Overweight and at Least One Weight-Related Comorbidity as of June 2026

MARA Rating Company June 16, 2026

Baxfendy / baxdrostat for treating uncontrolled or resistant hypertension as of June 2026

MARA Rating Company June 16, 2026

Belumosudil for chronic Graft-Versus-Host Disease After Failure of Prior Systemic Therapy as of June 2026

MARA Rating Company June 16, 2026

Hepcludex / bulevirtide for chronic Hepatitis Delta in Adults Without Cirrhosis or With Compensated Cirrhosis as of June 2026

MARA Rating Company June 16, 2026

Bysanti / milsaperidone for in the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder as of May 2026

MARA Rating Company May 28, 2026

Xolremdi / mavorixafor for wHIM syndrome in patients aged 12 years and older as of May 2026

MARA Rating Company May 28, 2026

Lurbinectedin for in Maintenance Treatment of Extensive-Stage SCLC After First-Line Induction Without Disease Progression as of May 2026

MARA Rating Company May 28, 2026

Levodopa-carbidopa intestinal gel for in Motor Fluctuations in Advanced Parkinson Disease as of May 2026

MARA Rating Company May 28, 2026

Leniolisib for in Activated Phosphoinositide 3-Kinase Delta Syndrome in Adults and Adolescents Weighing 45 Kilograms or More as of May 2026

MARA Rating Company May 28, 2026